| __timestamp | Gilead Sciences, Inc. | Pfizer Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 14097000000 |
| Thursday, January 1, 2015 | 3426000000 | 14809000000 |
| Friday, January 1, 2016 | 3398000000 | 14837000000 |
| Sunday, January 1, 2017 | 3878000000 | 14784000000 |
| Monday, January 1, 2018 | 4056000000 | 14455000000 |
| Tuesday, January 1, 2019 | 4381000000 | 14350000000 |
| Wednesday, January 1, 2020 | 5151000000 | 11615000000 |
| Friday, January 1, 2021 | 5246000000 | 12703000000 |
| Saturday, January 1, 2022 | 5673000000 | 13677000000 |
| Sunday, January 1, 2023 | 6090000000 | 14771000000 |
| Monday, January 1, 2024 | 6091000000 | 14730000000 |
Unleashing insights
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This chart provides a decade-long comparison of Selling, General, and Administrative (SG&A) expenses between Pfizer Inc. and Gilead Sciences, Inc., from 2014 to 2023.
Pfizer consistently outspent Gilead in SG&A expenses, with an average of $14 billion annually, nearly three times Gilead's average of $4.4 billion. Notably, Pfizer's expenses peaked in 2015 at $14.8 billion, while Gilead's expenses showed a steady increase, reaching $6.1 billion in 2023, a 104% rise from 2014.
These trends highlight Pfizer's aggressive market strategies and Gilead's gradual expansion. Investors and analysts can glean insights into each company's operational focus and market positioning, offering a window into their strategic priorities over the past decade.
Comparing SG&A Expenses: Novartis AG vs Gilead Sciences, Inc. Trends and Insights
Pfizer Inc. and Viatris Inc.: SG&A Spending Patterns Compared
Pfizer Inc. and Sarepta Therapeutics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Pfizer Inc. and Walgreens Boots Alliance, Inc.
Pfizer Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated
Gilead Sciences, Inc. vs Alnylam Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Regeneron Pharmaceuticals, Inc.
Gilead Sciences, Inc. vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and CRISPR Therapeutics AG
Comparing SG&A Expenses: Gilead Sciences, Inc. vs Galapagos NV Trends and Insights
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.